VVM
Versant Venture Management Portfolio holdings
AUM
$82.1M
This Quarter Return
-17.01%
1 Year Return
-26.22%
3 Year Return
+73.87%
5 Year Return
-1.11%
10 Year Return
+1,578.11%
AUM
$174M
AUM Growth
+$174M
(+121%)
Cap. Flow
+$107M
Cap. Flow
% of AUM
61.46%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
2
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Glaukos
GKOS
|
$76M |
| 2 |
Ocular Therapeutix
OCUL
|
$31.1M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 93.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Glaukos
GKOS
$5.5B
| $76M | 43.59% | +3,142,217 | New | +$76M |
|
|
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
| $37.5M | 21.49% | 407,416 | – | – |
|
|
3
Ocular Therapeutix
OCUL
$2.12B
| $31.1M | 17.86% | +2,215,384 | New | +$31.1M |
|
|
FPRX
4
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $16.8M | 9.64% | 1,092,152 | – | – |
|
|
AKAO
5
DELISTED
Achaogen, Inc.
AKAO
| $7.38M | 4.23% | 1,281,152 | – | – |
|
|
BITI
6
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
| $3.52M | 2.02% | 268,672 | – | – |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $2.03M | 1.17% | 1,048,601 | – | – |
|